Revenue: €4.1 million (+30% compared with the first half of the previous year)
Operating expenses: €15.3 million (+36%)
Cash consumption from operations: €11.3 million
Available cash: €34.4 million in cash + €3.0 million in non-risky financial assets (€2.9 million current + €0.1 million non-current)
Post-closing (November 2021) €3.1 million received in Research Tax Credit + €3.0 million loan received from Bpifrance + €1.0 million, partially collected, as a grant within the framework of the French Recovery Plan (Plan France Relance)
Contacts
MedinCell publishes its financial results and activity report for the first half of 2021-2022 (April – September 2021)
December 8, 2021